We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Lipid Vesicles Replace Blood in New Bacteria Test

By LabMedica International staff writers
Posted on 04 Oct 2017
Beta-hemolytic bacteria are those pathogens that are frequently to blame for illnesses that are spread among school children like Streptococcus, or those like Listeria that cause many foodborne illnesses. More...
The current test involves streaking a patient sample onto blood agar plates.

Tests do exist for the detection of particular beta-hemolytic species; however, these approaches are commonly based on the detection of genetic or antigenic determinants and not beta-hemolysis. Examples include the antibody–antigen tests, nucleic acid-based assay and more recent approaches using bacteriophages engineered with reporters.

Scientists at the Temasek Life Sciences Laboratory (Singapore) and their colleagues used the original blood agar test as inspiration for their new one. In the new assay, they placed fluorophores inside liposomes, which are lipid vesicles that have been used for controlled drug release. While in the liposome, the fluorescent molecules are packed together and are quenched, or dark, but when in the presence of beta-hemolytic bacteria, the liposome is broken open, the molecules are released, and they fluoresce.

The investigators used bacterial strains which were streaked on sheep blood agar and incubated at 37 °C overnight to check for hemolytic activity. The new test, called BETA, distinguished beta-hemolytic bacteria from control bacteria with 100 % accuracy in six hours on plates, and with 99% accuracy in liquid broth in an hour. The scientists say the method is rapid and cost-effective, which makes it ideal for diagnostics in developing countries. They also noticed that colony fluorescence associated with beta-hemolysis was qualitatively different from background fluorescence associated with control bacteria.

The authors concluded that BETA’s timeliness opens the door to applications once limited by the tardiness of blood agar cultures. With increased speed, gold standard throat cultures based on BETA can now be used as a first-choice diagnostic test (as opposed to a confirmatory assay) for bacterial pharyngitis. BETA’s scalable form-factor (multiwell plates) and low reagent costs (∼USD 0.02 per assay) make it suitable as a sensitive high-throughput triage method for in-plant food safety testing to complement pathogen-specific assays such as phage detection. The study was published on September 20, 2017, in the journal ACS Sensors.

Related Links:
Temasek Life Sciences Laboratory


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.